IP Library Granted Patent US 8,969,623
Granted Patent B2
US 8,969,623 · App. 14/052,116 · Granted Mar 3, 2015

Method for the preparation of cinacalcet and intermediates and impurities thereof

Inventors: Vijayavitthal Thippannachar Mathad (Maharashtra, IN); Navnath Chintaman Niphade (Maharashtra, IN); Gorakshanath Balasaheb Shinde (Maharashtra, IN); Sharad Subhash Ippar (Maharashtra, IN); Shrikant Prataprao Deshmukh (Maharashtra, IN); Raghavendra Kumar Panchangam (Maharashtra, IN)
Assignee: Amneal Pharmaceuticals, LLC
C07C209/62C07C211/30C07C251/16C07C251/24C07C251/30C07C249/02C07C251/06C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,969,623
App. No.
14/052,116
Granted
Mar 3, 2015
Kind
B2
Abstract

A method for the preparation of Cinacalcet is disclosed comprising treating (R)-1-naphthyl ethylamine with an aromatic aldehyde to form (1R)-1-(2-naphthyl)-N-(aryl methylene)ethanamine derivative of Formula (IV), which is further treated with 1-(3-halopropyl)-3-(trifluoromethyl)benzene of Formula (V) to obtain an iminium salt of Formula (VI), followed by hydrolysis to obtain Cinacalcet free base.

Claims (24)

1. A method of preparing a compound of Formula (I) or a salt thereof, comprising reacting a compound of Formula (IV) with a compound of Formula (V) to produce the compound of Formula (I),

wherein

Ar is benzyl-, phenyl- or naphthyl-, which may be mono- or di- or poly substituted with alkyl, aryl, alkoxy, amino, hydroxyl, halogen, and nitro groups, and X is chloro, bromo, or iodo.

2. The method of claim 1 , wherein

(a) the reaction of the compound of Formula (IV) with the compound of Formula (V) (1-(3-halopropyl)-3-(trifluoromethyl)benzene) forms an iminium salt of Formula (VI):

and

(b) the iminium salt of Formula (VI) is treated with water and/or acid solution to obtain the compound of Formula (I):

3. The method of claim 1 , wherein the compound of Formula (IV) and the compound of Formula (V) are reacted at a temperature of 80 to 180° C.

4. The method of claim 3 , wherein the reaction is carried out in the presence of a solvent.

5. The method of claim 4 , wherein the solvent is selected from an organic solvent, an inorganic solvent, or mixtures thereof.

6. The method of claim 4 , wherein the reaction is carried out at a reflux temperature of the solvent.

7. The method of claim 5 , wherein the organic solvent is selected from C2-C8 aliphatic amides, cyclic amides, dimethylsulfoxides, hydrocarbon solvents, alcoholic solvents, ether solvents, and mixtures thereof.

8. The method of claim 7 , wherein the C2-C8 aliphatic amide is selected from N,N-dimethylacetamide, dimethylformamide, hexamethylphosphoramide, and the like.

9. The method of claim 7 , wherein the cyclic amide is selected from 1,3-dimethyl-2-imidazolidinone (DMI), N-methyl-2-pyrrolidinone (NMP), and the like.

10. The method of claim 7 , wherein the hydrocarbon solvents are selected from toluene, xylene, and the like.

11. The method of claim 7 , wherein the alcoholic solvents are selected from methanol, ethanol, propanol, butanol, and the like.

12. The method of claim 7 , wherein the ether solvent is diglymes.

13. The method of claim 7 , wherein the organic solvent is N-methyl-2-pyrolidnone.

14. The method of claim 5 , wherein the inorganic solvent comprises an ionic liquid selected from 1-ethyl-3-methyl imidazolium ethylsulfate, [hmim]BF 4 , [hbim]Br, [hbim]Cl, [hbim]BF 4 , [hbim]PF 6 , [bbim]Br, [bbim]Cl, [bbim]ClO 4 , [bbim]BF 4 , [bmim]PF 6 , [bmim]BF 4 , and the like, and mixtures thereof.

15. The method of claim 2 , further comprising the addition of a catalyst.

16. The method of claim 15 , wherein the catalyst is selected from potassium iodide (KI), sodium iodide (NaI), or phase transfer catalysts selected from n-benzylcinchonidinium chloride, benzyltributylammonium chloride, 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide, phenyltrimethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium chloride, tricaprylmethylammonium chloride, tetrabutylammonium iodide, and the like, or combinations thereof.

17. The method of claim 3 , wherein the reaction is carried out at a temperature of 120 to 150° C.

18. The method of claim 2 , wherein the compound of Formula (V) is selected from 1-(3-chloropropyl)-3-(trifluormethyl)benzene, 1-(3-bromopropyl)-3-(trifluormethyl)benzene, or 1-(3-iodopropyl)-3-(trifluoromethyl)benzene.

19. The method of claim 2 , wherein the acid solution comprises concentrated hydrochloric acid.

Assignments (12)
PATENT SECURITY AGREEMENT Recorded Aug 1, 2025
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES, LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072312/0127 →
RELEASE OF SECURITY INTEREST IN PATENTS AT R/F 060050/0224 Recorded Jan 21, 2025
From: JPMORGAN CHASE BANK, N.A., AS AGENT
To: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
Reel/Frame 069958/0509 →
SECURITY INTEREST Recorded Nov 17, 2023
From: AMNEAL PHARMACEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065602/0692 →
PATENT SECURITY AGREEMENT Recorded Jun 10, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES LLC
To: TRUIST BANK. AS ADMINISTRATIVE AGENT
Reel/Frame 060329/0568 →
PATENT SECURITY AGREEMENT (TERM LOAN) Recorded May 12, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 060050/0224 →
RELEASE OF SECURITY INTEREST IN PATENTS (037112/0271) Recorded May 4, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, ACTING IN ITS CAPACITY AS THE SUCCESSOR ADMINISTRATIVE AGENT TO GENERAL ELECTRIC CAPITAL CORPORATION
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 046105/0097 →
RELEASE OF SECURITY INTEREST IN PATENTS (037112/0292) Recorded May 4, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, ACTING IN ITS CAPACITY AS THE SUCCESSOR ADMINISTRATIVE AGENT TO GENERAL ELECTRIC CAPITAL CORPORATION
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 046105/0172 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0292 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2014
From: MATHAD, VIJAYAVITTHAL THIPPANNACHAR; NIPHADE, NAVNATH CHINTAMAN; SHINDE, GORAKSHANATH BALASAHEB; IPPAR, SHARAD SUBHASH; DESHMUKH, SHRIKANT PRATAPRAO; PANCHANGAM, RAGHAVENDRA KUMAR
To: AMNEAL PHARMACEUTICALS, LLC; MEGAFINE PHARMA (P) LTD.
Reel/Frame 034049/0433 →
SECURITY INTEREST Recorded Jul 9, 2014
From: AMNEAL PHARMACEUTICALS LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 033283/0061 →
SECURITY INTEREST Recorded Jul 9, 2014
From: AMNEAL PHARMACEUTICALS LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 033282/0174 →
Priority Claims (1)
IN 516/MUM/2009 · Mar 9, 2009 · national
Continuity (3)
Continuation 13226061 · Sep 6, 2011
Continuation PCTIN2009000557 · Oct 8, 2009
Related Publication 20140081048A1 · Mar 20, 2014